The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients

AIM: Despite promising preclinical findings regarding clinical utility of farnesyltransferase inhibitors (FTI), such as lonafarnib, success of clinical trials is limited. A multicentre AGO-OVAR-15 phase II trial reported an unfavourable effect of lonafarnib on the outcome of patients with advanced o...

Full description

Saved in:
Bibliographic Details
Published in:Br J Clin Pharmacol
Main Authors: Bachmann, Hagen Sjard, Meier, Werner, du Bois, Andreas, Kimmig, Rainer, Kuhlmann, Jan Dominik, Siffert, Winfried, Sehouli, Jalid, Wollschlaeger, Kerstin, Huober, Jens, Hillemanns, Peter, Burges, Alexander, Schmalfeldt, Barbara, Aminossadati, Behnaz, Wimberger, Pauline
Format: Artigo
Language:Inglês
Published: John Wiley & Sons, Ltd 2015
Subjects:
Pharmacogenetics
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4631186/
https://ncbi.nlm.nih.gov/pubmed/26033044
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12688
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items